Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05908682 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Sponsor changed: Scynexis, Inc. to GlaxoSmithKline Show 4 more changesShow less
    • Start date: Jul 28, 2022 to Nov 12, 2025
    • Primary and study completion moved earlier from Oct 31, 2029 to Jul 31, 2029
    • Eligibility criteria expanded, about 7 words
    • Collaborators shortened, about 1 word
  2. Re-verified, no change to tracked fieldsv2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
This is an ongoing evaluation of subjects exposed to ibrexafungerp while pregnant. The study population will include pregnant women of any age.
Trial Details
NCT Number NCT05908682
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Vulvovaginitis, Candidal, Vulvovaginal Candidiasis, Candida Infection, Vaginal Candidiasis
Related terms Candidiasis, Candidiasis, Oral, Candidiasis, Vulvovaginal, Vulvovaginitis
Enrollment 100 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov